It was reported [34–36] that increased levels of HIF-1 or HIF-2 were correlated with adverse prognosis in breast, cervical, endometrial, colorectal, NSCLC, ovarian, rectal, pancreatic and prostate cancers. Here, HIF1A is linked to prostate carcinoma.